Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets
article
OA: closed
CC0
AI-generated summary
This study investigated how wetting agents and disintegrants affect the development of danazol nanocrystalline tablets, assessing their impact on tablet properties.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Poor wetting and/or particle aggregation are the shortcomings of the dried nanocrystalline suspensions, which subsequently might hinder the superior dissolution performance of the nano-crystalline suspensions. The objective of this study was to evaluate the effect of wetting agents and disintegrants on the dissolution performance of dried nanocrystals of an active pharmaceutical ingredient (API) with poor wetting property. Danazol, a BCS Class II compound with high LogP and low polar surface area, was chosen as a model compound for this study. Danazol nanocrystalline suspension was prepared by wet-media milling and converted into powder via spray granulation either with mannitol or microcrystalline cellulose as carriers at a drug: carrier ratio of 1:9 w/w. Danazol nanocrystalline suspension showed a superior dissolution performance compared to an un-milled danazol suspension. Dried danazol nanocrystals suffered from poor wetting leading to hindered dissolution performance i.e. ~ 40% and ~ 15% drug dissolution within 15 min for the mannitol and microcrystalline cellulose-based granules, respectively. Addition of a lipophilic surfactant (i.e. docusate sodium) at a surfactant: drug ratio of 0.015: 1 w/w during granulation helped in retaining the superior drug dissolution rates i.e. more than 80% drug dissolution within 15 min for mannitol-based granules by enhancing the wettability of dried danazol nanocrystals when compared to a hydrophilic surfactant (i.e. poloxamer 188) or disintegrant (i.e. sodium starch glycolate or croscarmellose sodium). The fast-dissolving mannitol-based granules containing danazol nanocrystals and docusate sodium were compressed into a tablet dosage form. The tablets containing danazol nanocrystals with docusate sodium showed a superior dissolution performance compared to a tablet containing un-milled danazol with docusate sodium.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids 1991
- Surface treatment of the hydrophobic drug danazol to improve drug dissolution 1998
- Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders 2014
- Rapid dissolving high potency danazol powders produced by spray freezing into liquid process 2003
References (43)
- Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders via openalex
- Rapid dissolving high potency danazol powders produced by spray freezing into liquid process via openalex
- Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids via openalex
- Surface treatment of the hydrophobic drug danazol to improve drug dissolution via openalex
- doi:10.1016/s0928-0987(96)00256-4 via openalex
- doi:10.1002/jps.2600670716 via openalex
- doi:10.2174/1381612821666150901100417 via openalex
- doi:10.1016/j.ejpb.2009.05.006 via openalex
- doi:10.1016/0378-5173(95)00033-f via openalex
- doi:10.1021/ma00111a026 via openalex
- doi:10.1208/pt0801009 via openalex
- doi:10.1016/j.ejps.2007.06.005 via openalex
- doi:10.1016/j.ejpb.2016.03.007 via openalex
- doi:10.1016/j.ijpharm.2007.02.005 via openalex
- doi:10.1016/j.ijpharm.2009.04.038 via openalex
- doi:10.1016/j.ejpb.2008.06.014 via openalex
- doi:10.1002/jps.24155 via openalex
- doi:10.1016/j.ijpharm.2019.118509 via openalex
- doi:10.1016/s0378-5173(97)00311-6 via openalex
- doi:10.1016/j.ejps.2008.06.009 via openalex
- doi:10.1016/j.addr.2007.05.003 via openalex
- doi:10.3390/pharmaceutics10030131 via openalex
- doi:10.1016/j.addr.2006.09.017 via openalex
- doi:10.1016/0021-9797(82)90128-x via openalex
- doi:10.1201/b14005-13 via openalex
- doi:10.1016/j.ijpharm.2019.03.007 via openalex
- doi:10.1016/j.ijpharm.2014.05.060 via openalex
- doi:10.1248/cpb.58.230 via openalex
- doi:10.1080/03639045.2016.1178770 via openalex
- doi:10.1016/b978-0-323-51255-8.00010-0 via openalex
- doi:10.1016/j.ijpharm.2014.11.043 via openalex
- doi:10.1002/jps.24426 via openalex
- doi:10.1208/s12249-016-0604-1 via openalex
- doi:10.1016/j.ijpharm.2019.04.050 via openalex
- doi:10.1016/j.ijpharm.2004.09.007 via openalex
- doi:10.1016/j.ejps.2012.04.020 via openalex
- doi:10.3390/pharmaceutics10030134 via openalex
- doi:10.1080/03639040500216097 via openalex
- doi:10.1016/j.ijpharm.2014.01.013 via openalex
- doi:10.1016/j.ijpharm.2005.05.014 via openalex
- doi:10.1201/9780849374555-4 via openalex
- doi:10.3109/10837450.2014.982822 via openalex
- doi:10.1016/0378-5173(86)90226-7 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:27:45.971503+00:00
- unpaywall
- last seen: 2026-06-05T02:00:03.366016+00:00
License: CC0
· commercial use OK